Navigating Heterogeneity and Harnessing Innovative Therapies in SLE
- Review the complex immunopathogenesis and clinical heterogeneity of SLE.
- Identify current gaps in biomarker-guided treatment and clinical monitoring.
- Evaluate the rationale and clinical evidence for emerging targeted therapies.
| Agenda - Friday 30 October | |
|---|---|
|
|
Chairperson: Prof Yoon-Kyoung Sung, Republic of Korea
|
|
1020 – 1030
|
Welcome and opening
Prof Yoon-Kyoung Sung, Republic of Korea |
|
1030 – 1045
|
Deciphering SLE Heterogeneity: From Pathogenesis to Prognosis
Prof Sandra Navarra, Philippines |
|
1045 – 1100
|
The Precision Gap: Current Limitations and the Need for Biomarkers Prof Chang-Hee Suh, Republic of Korea |
|
1100 – 1115
|
The Future Landscape: Novel Molecules and Targeted Approaches
TBC, TBC |
|
1115 – 1125
|
Q&A and closing Prof Yoon-Kyoung Sung, Republic of Korea Prof Sandra Navarra, Philippines Prof Chang-Hee Suh, Republic of Korea |
